Current immunosuppressive agents in pediatric renal transplantation: Efficacy, side-effects and utilization

Pediatric Transplantation

Volumn 8, Issue 5, 2004, Pages 445-453

  Smith, Jodi M ^a,c   Nemeth, Thomas L ^b   McDonald, Ruth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Immunosuppression; Pediatric; Renal transplant

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACNE; ADOLESCENT; ALOPECIA; ANAPHYLAXIS; ANTIBODY SPECIFICITY; ARTHRALGIA; ASEPTIC MENINGITIS; BONE NECROSIS; BULIMIA; CANCER; CATARACT; CHILD; CHILL; CUSHINGOID SYNDROME; DIARRHEA; DRUG EFFICACY; DYSPNEA; EXPERIENCE; FEVER; FLUID RETENTION; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPOTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LUNG EDEMA; MAINTENANCE THERAPY; MEGALOBLASTIC ANEMIA; MENTAL INSTABILITY; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; OBESITY; PANCREATITIS; PSYCHOSIS; REVIEW; SIDE EFFECT; STOMACH ULCER; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; UTILIZATION REVIEW;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 4644278718     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00209.x     Document Type: Review

References (68)

1. BENFIELD MR, STABLEIN D, TEJANI A. Trends in immunosuppressive therapy. Pediatr Transplant 1999: 3: 27-32.
2. North American Pediatric Renal Transplant Cooperative Study 2003 Annual Report.
3. HARIHARAN S. long-term renal transplant management: long-term kidney transplant survival. Am J Kidney Dis 2001: 38(Suppl. 6): S44-50.
4. MAYES JT, THISTLETHWAITE JJ, STUART JK, BUCKINGHAM MR, STUART FP. Reexposure to OKT3 in renal allograft recipients. Transplantation 1988: 45: 349.
5. COLE MS, STELLRECHT KE, SHI JD, et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 1999: 68: 545-554.
6. ETTENOER RB. Antibody therapy as an induction regimen in pediatric renal transplantation. Transplant Proc 1999: 31: 2677-2678.
7. BRENNAN DC, FLAVIN K, LOWELL JA. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999: 67: 1011-1018.
8. BRENNAN DC, FLAVIN JA, LOWELL JA. Leukocyte response to Thymoglobulin or Atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplant Proc 1999: 31: 16S-18S.
9. BELL L, GIRARDIN C, SHARMA A, GOODYER P, MAZER B. Lymphocyte subsets during and after rabbit anti-thymocyte globulin induction in pediatric renal transplantation: sustained T cell depletion. Transplant Proc 1997: 29: 6S-9S.
10. NASHAN B, MOORE R, AMLOT PL, et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997: 350: 1193.
11. KAHAN BD, RAJAGOPALAN PR, HALL MI. Reduction of the occurrence of acute cellular rejection among allograft recipients treated with basiliximab, a chimeric anit-interleukin-2 receptor monoclonal antibody. Transplantation 1999: 67: 276.
12. STERKERS G, BAUDOUIN V, ANSART-PIRENNE H, et al. Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, Basliximab, in pediatric kidney transplant recipients. Transplant Proc 2000: 32: 2757-2759.
13. KAHAN BD, RAJAGOPALAN PR, HALL M. United States simulect renal study group: reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2- receptor monoclonal antibody. Transplantation 1999: 67: 276-284.
14. BUMGARDNER GL, HARDIE I, JOHNSON RW, et al. Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001 Sep 15: 72: 839-845.
15. NASHAN B, LIGHT S, HARDIE IR, JOHNSON JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab double therapy study group. Transplantation 1999: 67: 110-115.
16. VINCENTI F, KIRKMAN R, LIGHT S. Interleukin-2-receptor blockade with daclizumab to prevent rejectionin renal transplantation. N Engl J Med 1998: 338: 1700-1701.
17. ETTENGER R, POTTER D, PESKOVITZ M, et al. Humanized monoclonal anti-interleukin-2 receptor (IL-2R) antibody daclizumab in pediatric renal transplantation. Transplantation 1998: 65: S16.
18. BENFIELD M, TEJANI A, PING-LEUNG H. Comparative study of the safety, efficacy, and practice patterns of monoclonal antibodies in pediatric renal transplantation. Am J Transplant 2002: 2(Suppl. 3): S192 (abstract from ATC 2002).
19. VINCENTI F, KIRKMAN R, LIGHT S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998: 338: 161-165.
20. KRENSKY AM, CLAYBERGER C. Transplantation immunology. Clin Immunol 1994: 41: 819-839.
21. SARWAL MM, YORGIN PD, ALEXANDER S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001: 72: 13-21.
22. HOYER PF, BOEKENKAMP A, VESTER U, OFFNER G, BRODEHL J. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients. Transplant Proc 1996: 28: 2259-2261.
23. FIRST MR, ALLOWAY R, SCHROEDER TJ. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. Clin Transplant 1998: 12: 518-524.
24. SCHROEDER TJ, LEVY R, POULETTY P, FIRST MR. A generic cyclosporine development program. Trans Proc 1997: 29: 1235-1238.
25. TEJANI A, HARMON WE. Clinical Transplantation. In: BARRATT MT, AVNER ED, HARMON WE, eds. Pediatric Nephrology, 4th edn. Baltimore, Maryland: Lippincott, Williams & Wilkins, 1999.
26. HARMON WE, SULLIVAN EK. Cyclosporine dosing and its relationship to outcome in pediatric renal transplantation. Kidney Int Suppl 1993: 43: S50-S55.
27. FELD LG, STABLEIN D, FIVUSH B, HARMON W, TEJANI A. Renal transplantation in children from 1987-1996: the 1996 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 1997: 1: 146-162.
28. TEJANI A, SULLIVAN EK. Higher maintenance cyclosporine dose decreases the risk of graft failure in North American children - a report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1996: 7: 550-555.
29. SHAW LM, HOLT DW, KEOWN P, VENKATARAMANAN R, YATSCOFF RW. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999: 21: 1632-1653.
30. MATAS AJ, GILLINGHAM KJ, CHAVERS BM. The importance of early cyclosporine levels in pediatric kidney transplantation. Clin Transplant 1996: 10: 482-486.
31. MEDEIROS M, PÉREZ-URIZAR J, MUÑOZ R, CASTAÑEDA- HERNÁDEZ G. Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sand-immune® or Neoral® cyclosporin A oral formulations. Pediatr Transplant 1999: 3: 225-230.
32. BELITSKY P, LEVY GA, JOHNSTON A. Neoral absorption profiling: an evolution in effectiveness. Transplant Proc 2000: 32(Suppl. 3A): 45S-52S.
33. JOHNSTON A, DAVID OJ, COONEY GF. Pharmacokinetic validation of neoral absorption profiling. Transplant Proc 2000: 32(Suppl.3A): 53S-56S.
34. BELITSKY P, DUNN S, JOHNSTON A, et al. Impact of absorption profiling on efficacy and safety of cyclosporine therapy in transplant recipients. Clinc Pharmacokinet 2000: 39: 117-125.
35. BARAMA A, FERNER F, BEAUREGARD-ZOLLINGER L, et al. for the neural phase IV study group. Absorption profiling of cyclosporine therapy for de novo kidney transplantation: a prospective randomized study comparing sparse sampling to trough monitoring [abstract no.190]. Transplantation 2000: 69(Suppl.): S162.
36. DAVID-NETO E. A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation. Pediatr Transplant 2002: 6: 313-318.
37. MARCH CL. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group. Ther Drug Monit 1999: 21: 27-34.
38. BALRAM C. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients. J Heart Lung Transplant 2002: 21: 1016-1021.
39. WACKE R. Comparison of several approaches for therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics. Eur J Clin Pharmacol 2000: 56: 43-48.
40. ELLIS D, SHAPIRO R, JORDAN ML, et al. Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 1994: 8: 193-200.
41. SHAPIRO R. Tacrolimus in pediatric renal transplantation: a review. Pediatr Transplant 1998: 2: 270-276.
42. SHAPIRO R, SCANTLEBURY VP, JORDAN ML, et al. FK 506 in pediatric kidney Transplantation-primary and rescue experience. Pediatric Nephrol 1995: 9: S43-S48.
43. BIRK PE, COOK ME, SCHMIDT WJ, CHAVERS BM. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single center report. Trans Proc 1996: 28: 993-994.
44. INGLE GR. Sirolimus: continuing the evolution of transplant immunosuppression. Ann Pharmacother 2000: 34: 1044-55.
45. KHANNA AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000: 70: 690-694.
46. SOLDNER A, CHRISTIANS U, SUSANTO M, WACHER VJ, SILVERMAN JA, BENET LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1999: 16: 478-485.
47. PREISS R. P-glycoprotein and related transporters. Int J Clin Pharmacol Ther 1998: 36: 3-8.
48. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321-1325.
49. SOLLINGER HW. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995: 60: 225-232.
50. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029-1037.
51. BENFIELD MR, SYMONS JM, BYNON S. Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999: 3: 33-37.
52. ETTENGER R, MENSTER M, WARSHAW B, et al. The long-term use of mycophenolate mofetil in pediatric renal transplantation. A report of the pediatric MMF study group. Transplantation 1999: 67: S124.
53. SEIKALY MG. Mycophenolate mofetil-is it worth the cost? The in-favor opinion. Pediatr Transplant 1999: 3: 79-82.
54. NEU AM, BENFIELD M. What is the role for mycophenolate mofetil in pediatric renal transplantation? Pediatr Transplant 1999: 3: 83-87.
55. GASTON RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001: 38(Suppl. 6): S25-S35.
56. TSAROUCHA AK, ZUCKER K, ESQUENAZI V, DE FARIA L, MILLER J, TZAKIS AG. Levels of mycophenolic acid and its glucuronide derivative in the plasma of liver, small bowel and kidney transplant patients receiving tacrolimus and cellcept combination therapy. Transpl Immunol 2000: 8: 143-146.
57. GRANGER DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001: 33: 3241-3244.
58. DUMONT FJ, STARUCH MJ, KOPRACH SL, et al. The immunosuppressive and toxic effects of FK 506 are mechanistically related: pharmacology of a novel antagonism of FK 506 and rapamycin. J Exp Med 1992: 176: 751-760.
59. BAEDER WL, ADAMS LM. Effect of Rapamycin, Cyclosporin A, and Prednisolone on Murine Thymocyte Proliferation In Vitro. Wyeth-Ayerst Research GTR-18812, 1989.
60. Sirolimus European Renal Transplant Study Group. Sirolimus-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999: 67: 1036-1042.
61. KAHAN BD. The potential role of rapamycin in pediatric transplantation as observed from adult studies. Pediatr Transplant 1999: 3: 175-180.
62. KAHAN BD. Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc 1998: 30: 2185-2188.
63. BRATTSTROM C, WILCEK H, TYDEN G: Hyperlipidemia in renal transplant recipients treated with sirolimus(rapamycin). Transplantation 1998: 65: 1272-1274.
64. STREIT F, CHRISTIANS U, SCHIEBEL HM, et al. Sensitive and specific quantification of sirolimus and its metabolites in blood of kidney graft recipients by HPLC/electorspray-mass spectrometry. Clin Chem 1996: 42: 1417-1425.
65. Sirolimus (package insert). Philadelphia, PA: Wyeth Laboratories, 2001.
66. MCALISTER VC. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002: 24: 346-350.
67. ORTA-SIBU N, CHANTLER C, BEWICK M, et al. Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. BMJ 1982: 285: 258-260.
68. CHAN L, GASTON R, HARIHARAN S. Evolution of immunosuppression and continued importance of acute rejection in renal transplantation. Am J Kidney Dis 2001 Dec: 38(Suppl. 6): S2-S9.